Data Sheet 1: BCL-XL in Myeloproliferative Neoplasm Progression

A 6.9 MB document by Chunyan Wu, last updated June 2, 2026, under a CC-BY-4.0 license. It details research on bone marrow mesenchymal stromal cells from patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis. The study analyzes fibrotic phenotype, apoptosis signaling, and the effects of BCL-XL and JAK2 inhibitors.

Use Cases

• Analyzing the role of BCL-XL in apoptosis resistance based on findings in malignant hematopoietic and fibrotic stromal cells.
• Studying fibrotic progression mechanisms based on the described myofibroblast-like phenotype and TGF-β/SMAD3 and JAK2/STAT3 pathway activation.
• Evaluating combined therapeutic strategies based on the described synergistic effects of BCL-XL and JAK2 inhibition in patient-derived cells.
• Investigating stromal-hematopoietic interactions in myeloproliferative neoplasms based on the analysis of bone marrow mesenchymal stromal cells.

Strengths

• Document is 6.9 MB, providing detailed methodological and results text.
• Research includes analysis of patient-derived cells from three distinct myeloproliferative neoplasms: PV, ET, and PMF.
• Findings are supported by multiple experimental techniques listed in the methods, such as flow cytometry and western blotting.

Limitations

• The primary data (e.g., raw measurements, cell counts) are not provided as a structured dataset; the file is a DOCX document summarizing research.
• Row and column counts for any underlying data are unknown, limiting suitability for direct computational analysis.
• The geographic or institutional source of the patient samples is not specified in the provided metadata.

Provenance

Source

Chunyan Wu, via figshare.

Collection Method

Analysis of bone marrow mesenchymal stromal cells from MPN patients using cell counting, immunofluorescence, flow cytometry, western blotting, and other laboratory techniques.

Freshness

Last updated 2026-06-02 05:40:27.